Maladie de Hodgkin avec atteinte médullaire

Presse Medicale - Tập 34 - Trang 227-229 - 2005
K. Doghmi1, J.-V. Malfuson1, M. El Ouennass2, T. Fagot1, A. Forel1, D. Branquet3, V. Foissaud2, T. Samson2, T. de Revel1, G. Nedellec1
1Service d’hématologie clinique, HIA Percy, Clamart (92)
2Laboratoire de biologie, HIA Percy, Clamart (92)
3Laboratoire d’anatomopathologie, HIA Percy, Clamart (92)

Tài liệu tham khảo

Linville, 1989, Hodgkin's disease presenting as myelofibrosis, Cancer, 15, 1720 Laplanche, 1981, L’atteinte médullaire initiale au cours de la maladie de Hodgkin, Nouv Presse Med, 10, 147 Krikorian, 1986, Hodgkin's disease presenting below the diaphragm, J Clin Oncol, 4, 1551, 10.1200/JCO.1986.4.10.1551 Duhamel, 1979, Formes médullaires massives de la maladie de Hodgkin et myélofibroses aiguës, Nouv Presse Med, 8, 1061 Fenaux, 1988, Maladie de Hodgkin révélée par une myélofibrose en apparence primitive : A propos de deux observations, Rev Med Interne, 9, 149, 10.1016/S0248-8663(88)80114-0 Talbot, 2001, 18-FDG positron imaging in clinical management of lymphoma patients, Crit Rev Oncol Hematol, 38, 193, 10.1016/S1040-8428(01)00127-5 Jerusalem, 2001, Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease, Haematologica, 86, 266 Delcambre, 2000, Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy, Eur J Nucl Med, 27, 176, 10.1007/s002590050024 Hueltenschmidt, 2001, Whole body positron emission tomography in the treatment of Hodgkin disease, Cancer, 91, 302, 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4 Bangerter, 1998, Whole body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDGPET) for accurate staging of Hodgkin's disease, Ann Oncol, 9, 1117, 10.1023/A:1008486928190 Kostacoglu, 2002, PET predicts prognosis after 1 cycle of chemotherapy in agressive lymphoma and Hodgkin's disease, J Nucl Med, 43, 1018 Jerusalem, 1999, Whole-body positron emission tomography using 18 F-Fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and pronostic value than classical computed tomography scan imaging, Blood, 94, 429, 10.1182/blood.V94.2.429 De Wit, 2001, 18FDGPET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma, Ann Oncol, 12, 29, 10.1023/A:1008357126404